Race and HIV clinical trial participation.

Purpose: This study was designed to examine at the role race/ethnicity plays in human immunodeficiency virus (HIV) clinical trial enrollment.

Background: HIV clinical trials are vitally important for improving knowledge about medications and their impact on the pathogenesis of HIV/AIDS. African Americans are disproportionately underrepresented in HIV clinical trials.

HIV-associated pseudotumor cerebri: a case report and literature review.

Idiopathic intracranial hypertension is a cause of vision loss in HIV-positive patients. In many patients with controlled HIV disease, idiopathic intracranial hypertension develops without any other apparent cause. We report the case of an HIV-infected man in whom idiopathic intracranial hypertension developed, and despite therapy with repeated lumbar puncture, acetazolamide, and neurosurgical interventions, he did not regain his vision.

Attitudes and perceptions of AIDS clinical trials group site coordinators on HIV clinical trial recruitment and retention: a descriptive study.

HIV-seropositive blacks, Hispanics, women of all ethnicities, and injection drug users (IDUs) have low rates of clinical trial participation. The opinions of research nurses and study coordinators as potential facilitators and barriers to access to clinical trials may contribute to this disparity. Study coordinators and research nurses from the adult AIDS Clinical Trials Group (ACTG) clinical trials units responded to an anonymous computer-based survey comprising multiple choice questions and clinical scenarios.